Skip to content

Exact Sciences beats, ups guidance

April 27, 2017

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.32), $0.09 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $48.4 million versus the consensus estimate of $37.29 million.


Exact Sciences sees FY2017 revenue of $195-205 million, versus the consensus of $178 million.

  • The company anticipates revenue of $195-205 million and completed Cologuard test volume of at least 470,000 tests during 2017. Previous guidance was $170-180 million in revenue and at least 415,000 completed Cologuard tests. For the second quarter, the company anticipates at least 115,000 completed Cologuard tests.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: